Lu Lu
Impact in
- Infectious Diseases top 0.05%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 detection and testing
- Virology top 0.5%
- HIV Research and Treatment
Papers in
-
- SARS-CoV-2 and COVID-19 Research 61
- HIV/AIDS drug development and treatment 50
- Viral gastroenteritis research and epidemiology 27
- COVID-19 Clinical Research Studies 24
- Virology 71
- HIV Research and Treatment 69
- Co-authors
- Shibo Jiang (149 shared papers)Shuai Xia (41 shared papers)Lanying Du (27 shared papers)Wei Xu (55 shared papers)Yun Zhu (22 shared papers)Tianlei Ying (13 shared papers)Zheng‐Li Shi (3 shared papers)Yanling Wu (8 shared papers)
- Journals
- Viruses (16 papers)PLoS ONE (11 papers)Microbes and Infection (11 papers)Emerging Microbes & Infections (10 papers)Journal of Virology (8 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Lu Lu
290 papers receiving 11.6k citations
Lu Lu's Hit Papers
Peers
Comparison fields: 5 of 165
- Infectious Diseases 6.6k
- Virology 1.1k
- Animal Science and Zoology 1.1k
- Immunology 1.9k
- Modeling and Simulation 268
Countries citing papers authored by Lu Lu
This map shows the geographic impact of Lu Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Lu more than expected).
Fields of papers citing papers by Lu Lu
This network shows the impact of papers produced by Lu Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Lu. The network helps show where Lu Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 305 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion Hit paper breakdown → | 2020 | 978 |
| 2 | Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody Hit paper breakdown → | 2020 | 838 |
| 3 | Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein Hit paper breakdown → | 2020 | 518 |
| 4 | A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike Hit paper breakdown → | 2019 | 374 |
| 5 | AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells Hit paper breakdown → | 2021 | 334 |
| 6 | Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade Hit paper breakdown → | 2019 | 333 |
| 7 | Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor Hit paper breakdown → | 2014 | 317 |
| 8 | 2020 | 237 | |
| 9 | Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients Hit paper breakdown → | 2021 | 234 |
| 10 | 2016 | 215 | |
| 11 | 2020 | 195 | |
| 12 | 2020 | 193 | |
| 13 | 2020 | 181 | |
| 14 | 2014 | 173 | |
| 15 | 2013 | 147 | |
| 16 | 2020 | 140 | |
| 17 | 2020 | 129 | |
| 18 | 2018 | 127 | |
| 19 | 2017 | 118 | |
| 20 | 2021 | 108 |
About Lu Lu
Lu Lu is a scholar working on Infectious Diseases, Virology, Epidemiology, Molecular Biology and Immunology, having authored 305 papers that have together received 11.8k indexed citations. Recurring topics across this work include HIV Research and Treatment (69 papers), SARS-CoV-2 and COVID-19 Research (61 papers), HIV/AIDS drug development and treatment (50 papers), Animal Virus Infections Studies (32 papers), Viral gastroenteritis research and epidemiology (27 papers), COVID-19 Clinical Research Studies (24 papers), Influenza Virus Research Studies (22 papers) and Immune Cell Function and Interaction (22 papers). The work is most often cited by research in Infectious Diseases (6.6k citations), Virology (1.1k citations), Animal Science and Zoology (1.1k citations), Immunology (1.9k citations) and Modeling and Simulation (268 citations). Lu Lu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Shibo Jiang, Shuai Xia, Lanying Du, Wei Xu, Yun Zhu, Tianlei Ying, Zheng‐Li Shi, Yanling Wu, Qian Wang and Qiaoshuai Lan. Their work appears in journals such as Viruses, PLoS ONE, Microbes and Infection, Emerging Microbes & Infections and Journal of Virology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.